Goldfinch Biopharma Funding: $160M Raised, Series B (2020)
Goldfinch Biopharma is based in Cambridge. It has raised $160M in total funding. Latest round: Series B.
Goldfinch Biopharma funding overview
Goldfinch Biopharma is based in Cambridge. Goldfinch Biopharma has raised $160M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in June 2020. The round record for Goldfinch Biopharma runs through 2020; nothing later has been disclosed. Investors on record include Third Rock Ventures, Gilead Sciences, Eventide Asset Management, Wellington Management Company, Ally Bridge Group, Casdin Capital and 4 others. 10 distinct backers are named across the disclosed rounds.
Goldfinch Biopharma at a glance
Total raised
$160M
Latest round
Series B
Latest round date
June 2020
Headquarters
Cambridge
Notable investors
Third Rock Ventures, Gilead Sciences, Eventide Asset Management, Wellington Management Company, Ally Bridge Group, Casdin Capital, Irving Investors, Yonjin Capital
Frequently asked about Goldfinch Biopharma funding
How much has Goldfinch Biopharma raised?
Goldfinch Biopharma has raised $160M in total disclosed funding across the rounds on record.
Who has invested in Goldfinch Biopharma?
Third Rock Ventures, Gilead Sciences, Eventide Asset Management, Wellington Management Company, Ally Bridge Group, Casdin Capital are named among the investors backing Goldfinch Biopharma.
What was the latest Goldfinch Biopharma funding round?
The most recent disclosed round is a Series B, announced in June 2020.
Where is Goldfinch Biopharma based?
Goldfinch Biopharma is based in Cambridge.
When did Goldfinch Biopharma last raise?
The last disclosed Goldfinch Biopharma round closed in June 2020 at Series B.
Goldfinch Biopharma totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Cambridge below to benchmark round size and investor mix.
